Investors & Media Financials & Filings Investor Relations Overview Corporate Governance Press Releases & Statements Events & Presentations SEC Filings Annuals and Proxies Investor FAQs Financials & Filings Quarterly Results Stock Information Analyst Coverage Email Alerts Subscription Notice of Pendency of Settlement of Action Financials & Filings Show all 2024 Third Quarter Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates Form 10-Q Annual Reports Title View 2023 Annual Report 2023 Annual Report 976.4 KB 2022 Annual Report 2022 Annual Report 824.1 KB Proxy Statements Title View 2024 Proxy Statement 2024 Proxy Statement 2.5 MB Form 10-K Filing date View Feb 14, 2024 View HTML 0000950170-24-014934.pdf 0000950170-24-014934.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA Form 10-Q Filing date View Oct 29, 2024 0000950170-24-118256.pdf 0000950170-24-118256.rtf 0000950170-24-118256.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML Jul 31, 2024 0000950170-24-088593.pdf 0000950170-24-088593.rtf 0000950170-24-088593.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Financials & Filings Show all 2024 Third Quarter Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates Form 10-Q Annual Reports Title View 2023 Annual Report 2023 Annual Report 976.4 KB 2022 Annual Report 2022 Annual Report 824.1 KB Proxy Statements Title View 2024 Proxy Statement 2024 Proxy Statement 2.5 MB Form 10-K Filing date View Feb 14, 2024 View HTML 0000950170-24-014934.pdf 0000950170-24-014934.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA Form 10-Q Filing date View Oct 29, 2024 0000950170-24-118256.pdf 0000950170-24-118256.rtf 0000950170-24-118256.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML Jul 31, 2024 0000950170-24-088593.pdf 0000950170-24-088593.rtf 0000950170-24-088593.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
